study to assess safety and tolerability of AZD4547 in Japanese patient
Study identifier:D2610C00002
ClinicalTrials.gov identifier:NCT01213160
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
A Phase I, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of Ascending Doses of AZD4547 in Japanese Patients with Advanced Solid Malignancies
Medical condition
cancer
Phase
Phase 1
Healthy volunteers
No
Study drug
AZD4547
Sex
All
Actual Enrollment
40
Study type
Interventional
Age
25 Years - 150 Years
Date
Study Start Date: 01 Nov 2010
Primary Completion Date: 01 Jun 2013
Study Completion Date: 01 Jun 2013
Study design
Allocation: N/A
Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Verification:
Verified 01 Jun 2016 by AstraZeneca
Sponsors
AstraZeneca
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|---|
| Experimental: AZD4547 | Drug: AZD4547 film coated tablet, PO, twice daily |
Contacts
Investigators
Principal Investigator
Paul Stockman
AstraZeneca
